Adenosine Deaminase

Measurement of Activity and Use of Inhibitors
  • Ram P. Agarwal


The physiologic and pharmacologic importance of purines, adenosine, and their analogs as regulators of blood flow, lipolysis, neurotransmission, and immune functions and their antineoplastic activity has been reviewed in this volume and elsewhere (Burnstock, 1981; Schubert et al., 1979; Suhadolnik, 1970). The enzyme adenosine deaminase (ADA; adenosine aminohydrolase, EC, which plays an important role in the regulation of adenosine and its analogs, is the subject of the present discussion.


Adenosine Deaminase Severe Combine Immunodeficiency Purine Nucleoside Purine Nucleoside Phosphorylase Adenosine Kinase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adamson, R. H., Zaharevitz, D. W., and Johns, D. G. 1977. Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2’-deoxy coformycin. Pharmacology, 75: 84–89.CrossRefGoogle Scholar
  2. Agarwal, R. P. 1979. Recovery of 2’-deoxycoformycin-inhibited adenosine deaminase of mouse eryth-rocytes and leukemia L1210 in vivo. Cancer Res, 39: 1425–1427.PubMedGoogle Scholar
  3. Agarwal, R. P. 1980. In vivo inhibition of adenosine deaminase by 2’-deoxycoformycin in mouse blood and leukemia LI210 cells. Biochem. Pharmacol, 29: 187–193.PubMedCrossRefGoogle Scholar
  4. Agarwal, R. P. 1982. Inhibitors of adenosine deaminase. Pharmacol. Ther. 17:399–429. Agarwal, R. P., Sagar, S. M., and Parks, R. E., Jr. 1975. Adenosine deaminase from human erythrocytes: Purification and effects of adenosine analogs. Biochem. Pharmacol, 24: 693–701.Google Scholar
  5. Agarwal, R. P., Crabtree, G. W., Parks, R. E., Jr., Nelson, J. A. Keightley, R., Parkman, R., Rosen, R. Stern, R. C., and Polmar, S. H. 1976. Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency. J. Clin. Invest, 57: 1025–1035.PubMedCrossRefGoogle Scholar
  6. Agarwal, R. P., Spector, T., and Parks, R. E., Jr. 1977. Tight-binding inhibitors IV: Inhibition of adenosine deaminase by various inhibitors. Biochem. Pharmacol, 26: 359–367.PubMedCrossRefGoogle Scholar
  7. Agarwal, R. P., Major, P. P., and Kufe, D. W. 1982a. Simple and rapid high-performance liquid chromatographic method for analysis of nucleosides in biological fluids. J. Chromatogr, 231: 418–424.PubMedCrossRefGoogle Scholar
  8. Agarwal, R. P., Blatt, J., Miser, J., Sallan, S., Lipton, J. M., Reaman, G. H., Holcenberg, J., and Poplack, D. G. 1982b. Clinical pharmacology of 9-β-D arabinofuranosyl adenine in combination with 2’-deoxycoformycin. Cancer Res, 42: 3884–3886.PubMedGoogle Scholar
  9. Arch, J. R. S. and Newsholme, E. A. 1978. Activities and some properties of 5’-nucleotidase, adenosine kinase and adenosine deaminase in tissues from vertebrates in relation to the control of the concentration and the physiological role of adenosine. Biochem. J, 774: 965–977.Google Scholar
  10. Anderson, E. P. 1973. Nucleoside and nucleotide kinases. The Enzymes, 9: 49–96.CrossRefGoogle Scholar
  11. Baker, D. C., Hanvey, J. C., Hawkins, L. D. and Murphy, J. 1981. Identification of the bioactive enantiomer of erythro-3-(adenine-9yl)-2-nonanol (EHNA), a semi-tight binding inhibitor of adenosine deaminase. Biochem. Pharmacol, 30: 1159–1160.PubMedCrossRefGoogle Scholar
  12. Barton, R., Martiniuk, F., Hirschhorn, R., and Goldschneider, I. 1980. Inverse relationship between adenosine deaminase and purine nucleoside phosphorylase in rat lymphocyte population. Cell. Immunol, 49: 208–214.PubMedCrossRefGoogle Scholar
  13. Bastian, G., Bessodes, M., Panzica, R. P., Abushanab, E., Chen, S. F., Stoeckler, J. D. and Parks, R. E., Jr. 1981. Adenosine deaminase inhibitors. The conversion of a single chiral synthon into erythro and threo-9-(2-hydroxy-3 nonyl) adenine. J. Med. Chem, 24: 1383–1384.PubMedCrossRefGoogle Scholar
  14. Ben-Basset, I., Simoni, F., Holtzman, F., and Ramot, B. 1979. Adenosine deaminase activity of normal lymphocytes and leukemic cells. Israel J. Med. Sci, 75: 925–927.Google Scholar
  15. Bessodes, M. D., Bastian, G., Abushanab, E., Panzica, R. P., Berman, S. F., Marcaccio, E. J., Jr., Chen, S. F., Stoeckler, J. D., and Parks, Jr. 1981. Effect of chirality in erythro-9-(2-hydroxy-3- nonyl) adenine. Biochem. Pharmacol, 37: 879–882.Google Scholar
  16. Blatt, J., Reaman, G., Poplack, D. G. 1980. Biochemical markers in lymphoid malignancy. N. Engl. J. Med, 303: 918–922.PubMedCrossRefGoogle Scholar
  17. Burnstock, G. 1981. Neurotransmitters and trophic factors in the autonomic nervous system. J. Physiol, 5 /3: 1–35.Google Scholar
  18. Caron, N., Lee S. H., and Kimball, A. P. 1977. Effect of 2’-deoxycoformycin, 9-(3-D-arabinofura- nosyladenine-5’-phosphate, and l-p-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210. Cancer Res, 37: 3274–3279.PubMedGoogle Scholar
  19. Cass, C. E., and Au-Yeung, T. H. 1976. Enhancement of 9-(3-D-arabinofuranosyl adenine cytotoxicity to mouse leukemia L1210 in vitro by 2’-deoxycoformycin. Cancer Res, 36: 1486–1491.PubMedGoogle Scholar
  20. Cha, S. 1975. Tight-binding inhibitors: I. Kinetic behavior. Biochem. Pharmacol, 24: 2177–2185.PubMedCrossRefGoogle Scholar
  21. Cha, S. 1976. Tight-binding inhibitors: III. A new approach for the determination of competition between tight-binding inhibitors and substrates—inhibition of adenosine deaminase by cofor- mycin. Biochem. Pharmacol, 25: 2695–2702.PubMedCrossRefGoogle Scholar
  22. Cha, S., Agarwal, R. P. and Parks, R. E., Jr. 1975. Tight-binding inhibitors: II. Non-steady state nature of inhibition of milk xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin. Biochem. Pharmacol, 24: 2187–2197.PubMedCrossRefGoogle Scholar
  23. Chaney, A. L., and Marbach, E. P. 1962. Modified reagents for determination of urea and ammonia. Clin. Chem, 5: 130–132.Google Scholar
  24. Chassin, M. M., Chirigos, M. A., Johns, D. G. and Adamson, R. H. 1977. Adenosine deaminase inhibition for immunosuppressive. N. Engl. J. Med, 296: 1232.Google Scholar
  25. Coleman, M. S., Greenwood, M. F., Hutton, J. J., Holland, P., Lampkin, B., Krill, C., and Kastelic, J. E. 1978. Adenosine deaminase, terminal deoxynucleotidyl transferase (TdT), and cell surface markers in childhood acute leukemia. Blood, 52: 1125–1131.PubMedGoogle Scholar
  26. Conner, J. D., Sweetman, L., Carey, S., Stuckey, M. A., and Buchanan, R. 1974. Effect of adenosine deaminase upon the antiviral activity in vitro of adenine arabinoside for vaccinia virus. Antimicrob. Ag. Chemother, 6: 630–636.CrossRefGoogle Scholar
  27. Dissing, J., and Knudsen, B. 1972. Adenosine deaminase deficiency and combined immunodeficiency syndrome. Lancet, 2: 1316.PubMedCrossRefGoogle Scholar
  28. Evans, B., and Wolfenden, R. 1970. A potential transition-state analog for adenosine deaminase. J. Am. Chem. Soc, 92: 4751–4752.PubMedCrossRefGoogle Scholar
  29. Falcon, M. G., and Jones, B. R. 1977. Antiviral activity in the rabbit cornea of adenine arabinoside, Ara-A 5’-monophosphate, and hypoxanthine arabinoside; and interaction with adenosine deaminase inhibitor. J. Gen. Virol, 36: 199–202.PubMedCrossRefGoogle Scholar
  30. Giblett, E. R., Anderson, J. E., Cohen, F., Pollara, B., and Meuwissen, H. J. 1972. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet, 2: 1067–1069.PubMedCrossRefGoogle Scholar
  31. Glazer, R. I., and Peale, A. L. 1978. Cordycepin and xylosyladenine: Inhibitors of methylation of nuclear RNA. Biochem. Biophys. Res. Commun, 57: 521–526.CrossRefGoogle Scholar
  32. Grever, M., Coleman, M. S., Balcerzak, S. P. 1983. Adenosine deaminase and terminal deoxynu- cleotidyl transferase: biochemical markers in the management of chronic myelogeneous leukemia. Cancer Res, 43: 1442–1445.PubMedGoogle Scholar
  33. Hartwick, R., Jeffries, A., Krstulovic, A., and Brown, P. R. 1978. An optimized assay for adenosine deaminase using reverse phase high pressure liquid chromatography. J. Chromatgr, 76: 427–435.Google Scholar
  34. Hopkinson, D. A., Cook, P. J. L., and Harris, H. 1969. Further data on the adenosine deaminase (ADA) polymorphism and a report of a new phenotype. Ann. Hum. Genet, 52: 361–367.CrossRefGoogle Scholar
  35. Kedar, A., Tritsch, G. L., Freeman, A. I. 1980. Transient stimulatory adenosine deaminase activity in peripheral lymphocytic lysate from a case of T-cell lymphoma. Res. Commun. Chem. Pathol. Pharmacol, 28: 153–162.PubMedGoogle Scholar
  36. Koehler, L. H., and Benz, E. J. 1962. Serum adenosine deaminase: Methodology and clinical application. Clin. Chem, 8: 133–140.PubMedGoogle Scholar
  37. Killer, C. A., Mitchell, B. S., Grever, M. R., Mejais, E., Malspeis, L.,andMetz, E. N. 1979. Treatment of acute lymphoblastic leukemia with 2’-deoxycoformycin: Clinical and biochemical consequences of adenosine deaminase (EC inhibition. Cancer Treat. Rep., 65: 1949–1952.Google Scholar
  38. Koya, M., Kansh, T., Sawada, H., Uchino, H., and Neda, K. 1981. Adenosine deaminase and ecto- 5’-nucleotidase activities in various leukemias with special reference to blast crisis of chronic myeloid leukemia. Blood, 55: 1107–1111.Google Scholar
  39. Kvamme, E., Tveit, B., and Svennedy, G. 1965. Glutaminase from pig kidney, an allossteric protein. Biochem. Biophys. Res. Commun, 20: 566–572.PubMedCrossRefGoogle Scholar
  40. Lee, C. H., Evan, S. P., Rosenberg, M. C., Bagnara, A. S., Ziegler, J. B., and Van der Wyden, M. D. 1979. In vitro platelet abnormality in adenosine deaminase deficiency and severe combined immunodeficiency. Blood, 53: 465–471.PubMedGoogle Scholar
  41. Lum, C. T., Sutherland, D. E. R., Yasmineh, W. G., and Najarian, J. S. 1978. Peripheral blood mononuclear cell adenosine deaminase activity in renal allograft recipients. J. Surg. Res, 24: 388–395.PubMedCrossRefGoogle Scholar
  42. Lum, C. T., Sutherland, D. E. R., Yashmineh, D. S., Howard, R. J., and Najarian, J. S. 1979. Adenosine deaminase activity in cytomegolovirus related graft and patient loss. Transplantation Proc, 77: 83–88.Google Scholar
  43. Major, P. P., Agarwal, R. P., and Kufe, D. W. 1981a. Deoxycoformycin: Neurological toxicity. Cancer Chemother. Pharmacol, 5: 193–196.PubMedCrossRefGoogle Scholar
  44. Major, P. P., Agarwal, R. P., and Kufe, D. W. 1981b. Clinical pharmacology of deoxycoformycin. Blood, 58: 91–96.PubMedGoogle Scholar
  45. Major, P. P., Agarwal, R. P., and Kufe, D. W. 1983. Clinical pharmacology of arabinosyladenine in combination with deoxycoformycin. Cancer Chemother. Pharmacol, 70: 125–128.CrossRefGoogle Scholar
  46. Meier, J., Coleman, M. S., and Hutton, J. J. 1976. Adenosine deaminase activity in peripheral blood cells of patients with hematologic malignancies. Br. J. Cancer, 55: 312–319.CrossRefGoogle Scholar
  47. Meuwissen, H. J., Pollara, B., and Pickering, R. J. 1975. Combined immunodeficiency disease associated with adenosine deaminase. J. Pediatr, 86: 169–181.PubMedCrossRefGoogle Scholar
  48. Miwa, S., Fuji, H., Matsumoto, N., Nakatsuji, T., Oda, S., Asano, H., Asano, S., and Miura, Y. 1978. A case of red cell adenosine deaminase over production associated with hereditary hemolytic anemia found in Japan. Am. J. Hematol, 5: 107–115.PubMedCrossRefGoogle Scholar
  49. Muller, W. E. G., Zahn, R. K., Arendez, J., Maidhof, A., and Umezawa, H. 1978. Influence of coformycin on the cytostatic activity of 9-(3-D-Arabinofuranosyladenine and adenosine in mouse L5178Y cells. Hoppe-Seyler’s Z. Physiol. Chem, 559: 1287–1295.CrossRefGoogle Scholar
  50. Nakamura, H., Koyama, G., Iitaka, Y., Ohno, M., Yagisawa, N., Kondo, S., Maeda, K., and Umezawa, H. 1974. Structure of coformycin, an unusual nucleoside of microbial origin. J. Am. Chem. Soc, 96: 4327–4328.PubMedCrossRefGoogle Scholar
  51. Nakamura, H., Koyama, G., Umezawa, H., and Iitaka, Y. 1976. The crystal and molecular structure of coformycin. Acta Cryst, B32: 1206–1212.CrossRefGoogle Scholar
  52. Newby, A. C. 1980. Role of adenosine deaminase, ecto (5’-nucleotidase) and ecto (non-specific phosphatase) in cyanide-induced adenosine monophosphate catabolism in rat polymorphonuclear leucocytes. Biochem. J, 756: 907–918.Google Scholar
  53. Nishihara, H., Akedo, H., Okada, H., and Hattori, S. 1970. Multienzyme patterns of serum adenosine deaminase by agar gel electrophoresis. Clinica. Chim. Acta, 30: 251–258.CrossRefGoogle Scholar
  54. Nishihara, H., Ishikawa, S., Shinkai, K., and Akedo, H. 1973. Multiple forms of human adenosine deaminase. Biochem. Biophys. Acta, 302: 429–442.PubMedCrossRefGoogle Scholar
  55. North, T. W., and Cohen, S. S. 1978. Erythro-9-(2-hydroxy-3-nonyl) adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues. Proc. Nat. Acad. Sci. USA, 75: 4684–4688.PubMedCrossRefGoogle Scholar
  56. Nygaard, P. 1978. Adenosine deaminase from Escherichia coli. Methods Enzymol, 57: 508–512.CrossRefGoogle Scholar
  57. Orfanos, A. P., Nylor, E. W., and Guthrie, R. 1978. Micromethod for estimating adenosine deaminase activity in dried blood spots on filter paper. Clin. Chem, 24: 591–594.PubMedGoogle Scholar
  58. Parkman, R. G., Gelfand, F. W., Rosen, F., Sanderson, A., and Hirschhorn, R. 1975. Severe combined immunodeficiency disease associated with adenosine deaminase deficiency. N. Engl. J. Med, 292: 714–719.PubMedCrossRefGoogle Scholar
  59. Parks, R. E., Jr., and Brown, P. R. 1973. Incorporation of nucleosides into the nucleotide pools of human erythrocytes, adenosine and its analogs. Biochemistry, 12: 3294–3302.PubMedCrossRefGoogle Scholar
  60. Pauling, L. 1948. Chemical achievement and hope for the future. Am. Scientist, 16: 51–58.Google Scholar
  61. Polmar, S. H., Stern, R. C., Schwartz, A. L., Wetzler, E. M., Chase, P. A., and Hirschhorn, R. 1976. Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. TV. Engl. J. Med, 295: 1337–1343.CrossRefGoogle Scholar
  62. Prentice, H. G., Smyth, J. F., Ganeshguru, K., Wonk, B., Bradstock, K. F., Janossy, G., Goldstone, A. K., and Hoffbrand, A. V. 1980. Remission induction with adenosine deaminase inhibitor 2’- deoxycoformycin in Thy-lymphoblastic leukemia. Lancet. 2: 170–172.PubMedCrossRefGoogle Scholar
  63. Rodbard, D., Bridson, W., and Rayford, P. L. 1969. Rapid calculation of radioimmunoassay results. Lab. Clin. Med, 74: 110–118.Google Scholar
  64. Rogler-Brown, T., Agarwal, R. P., and Parks, R. E., Jr. 1978. Tight-binding inhibitors. VI. Interactions of deoxycoformycin and adenosine deaminase in intact human enthrocytes and Sarcoma 180 cells. Biochem. Pharmacol, 27: 2289–2296.PubMedCrossRefGoogle Scholar
  65. Sawa, T., Fukagawa, Y., Homma, I., Takeuchi, T., and Umezawa, H. 1967a. Mode of inhibition of coformycin on adenosine deaminase. J. Antiobiotics (Japan) Ser.A, 20: 221–231.Google Scholar
  66. Sawa, T., Fukagawa, Y., Homma, I., Takeuchi, T., and Umezawa, H. 1967b. Formycin deaminating activity of microorganisms. J. Antibiotics (Japan) Ser. A, 20: 317–321.Google Scholar
  67. Schaeffer, H. J., 1971. Factors in the design of reversible and irreversible enzyme inhibitors. In: Drug Design: pp. 129–159. Medicinal Chemistry, Volume 11-Pt. II Ed. by Ariens, E. J. Academic Press, New York.Google Scholar
  68. Schaeffer, H. J., and Schwender, C. F. 1974. Enzyme inhibitors. 26. Bridging hydrophobic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl) adenines. J. Med. Chem, 77: 6–8.CrossRefGoogle Scholar
  69. Scholar, E. M., and Calabresi, P. 1973. Identification of the enzymic pathway of nucleotide metabolism in human lymphocytes and leukemia cells. Cancer Res, 33: 94–103.PubMedGoogle Scholar
  70. Schroder, H. C. Schuster, D. K., Zahn, R. K., and Muller, W. E. G. 1981. A novel metabolic effect of the adenosine deaminase inhibitor coformycin, a potentiator of antiviral adenosine analogues. Antiviral Res, 7: 383–391.Google Scholar
  71. Schubert, P., Reddington, M., and Kreutzberg, G. W. 1979. On the possible role of adenosine as a modulatory messenger in the hippocampus and other regions of the CNS. Prog. Brain Res, 57: 149–165.CrossRefGoogle Scholar
  72. Seligson, D., and Seligson, H. 1951. A microdiffusion method for the determination of nitrogen liberated as ammonia. J. Lab. Clin. Med, 8: 324–330.Google Scholar
  73. Shimazaki, M., Kondo, S., Maeda, K., Ohno, M., and Umezawa, H. 1979a. Synthesis of isocoformycin, an aadenosine deaminase inhibitor of synthetic origin. J. Antibiotics (Japan), 12: 537–538.CrossRefGoogle Scholar
  74. Shimazaki, M., Kumada, Y., Takeuchi, T., Umezawa, H., and Watanabe, K. 1979b. Studies on inhibition of adenosine deaminase by isocoformycin in vitro and in vivo. J. Antibiotics (Japan), 32: 654–658.CrossRefGoogle Scholar
  75. Sidi, Y., Boer, P. Pick, I., Pinkhas, J., Sperling, O. 1979. Increased adenosine deaminase activity in peripheral lymphocytes in Waldenstrom’s macroglubulinaemia. Lancet, 7: 500.CrossRefGoogle Scholar
  76. Sloan, B. J., Kielty, J. K., and Miller, F. A. 1977. Effect of a novel adenosine deaminase inhibitor (Co-vidarabine, CoV) upon the antiviral activity in vitro and in vivo of vidarabin (Vira-A™) for DNA viral replication. Ann. N.Y. Acad. Sci, 284: 60–80.PubMedCrossRefGoogle Scholar
  77. Smyth, J. F., and Harrap, K. R. 1975. Adenosine deaminase in leukemia. Br. J. Cancer, 31: 544–549.PubMedCrossRefGoogle Scholar
  78. Smyth, J. F., Poplack, D. G., Holiman, B. J., and Leventhal, B. G. 1978. Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia. J. Clin. Invest, 62: 710–712.PubMedCrossRefGoogle Scholar
  79. Smyth, J. F., Chassin, M. M., Harrap, K. R. x Adamson, R. H., and Johns, D. G. 1979. 2’-Deoxy- coformycin (DCF): Phase I trial and clinical pharmacology. Proc. Am. Assoc. Cancer Res, 20: 41.Google Scholar
  80. Stubbs, G., Litt, M., Lis, E., Jackson, R., Voth, W., Lindberg, A., and Litt, R. 1982. Adenosine deaminase activity decreased in autism. J. Am. Acad. Child. Psych, 27: 71–74.Google Scholar
  81. Sufrin, G., Tritsch, G., Mittleman, A., Moore, R. H., and Murphy, G. P. 1977. Adenosine deaminase activity in patients with renal adenocarcinoma. Cancer, 40: 796–802.PubMedCrossRefGoogle Scholar
  82. Sufrin, G., Tritsch, G. L., Mittleman, A., and Murphy, G. P. 1978. Studies of lymphocyte adenosine deaminase activity in patients with renal and transitional cell carcinoma. Int. Adv. Surg. Oncol, 7: 11–28.Google Scholar
  83. Suhadolnik, R. J. 1970. Nucleoside Antibiotics. Wiley, New York.Google Scholar
  84. Tritsch, G. L., and Minowada, J. 1978. Differences in purine metabolizing enzyme activities in human leukemia T-cell, B-cell and null-cell lines. J. Natl. Cancer Inst, 60: 1301–1304.PubMedGoogle Scholar
  85. Trotta, P. P., and Balis, M. E. 1977. Structural and kinetic alterations in adenosine deaminase as-sociated with the differentiation of rat intestinal cells. Cancer Res, 37: 2297–2305.PubMedGoogle Scholar
  86. Trotta, P. P., Tedde, A., and Balis, M. E. 1980. Effects on immune function of continuous infusion into mice of 2’-deoxycoformycin (DCF). Proc. Am. Assoc. Cancer Res, 21: 242.Google Scholar
  87. Uitendaal, M. P., DeBruyn, C. H. M. M., Oei, T. L., Geerts, S. J., and Hosli, P. 1978. Fluctuating adenosine deaminase activities in cultured fibroblasts, Biochem. Med, 20: 54–62.CrossRefGoogle Scholar
  88. Vaca, G., Sanchez-Corona, J., Olivares, N., Medina, C., Ibara, B., and Cantu, J. M. 1979. A simple rapid fluorescent assay for adenosine deaminase activity. Ann. Genet, 22: 182–184.PubMedGoogle Scholar
  89. Wierzchowski, J., and Shugar, D. 1983. Sensitive fluorimetric assay for adenosine deaminase with formycin as substrate; and substrate and inhibitor properties of some pyrazolopyrimidine and related analogues. Z. Naturforsch, 38c: 61–13.Google Scholar
  90. Wiginton, D. A., Coleman, M. S., and Hutton, J. J. 1981. Purification, characterization and radioim-munoassay of adenosine deaminase from human leukemic granulocytes Biochem. J, 195: 389–397.PubMedGoogle Scholar
  91. Woo, P. W. K., Dion, H. W., Lang, S. M., Dahl, L. F., and Durham, L. J. 1974. A novel adenosine and Ara-A deaminase inhibitor (R)-3-(2-deox-β-D-erythropentofuranosyl)-3,6,7,8-tetrahydroimi-dazo-[4,5-d] [1,3] diazepin-8-ol.Google Scholar
  92. Zielke, C. L., and Suelter, C. H. 1971. Purine nucleoside, and purine nucleotide aminohydrolases. The Enzymes, 4: 41–18.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • Ram P. Agarwal
    • 1
    • 2
    • 3
  1. 1.Section of Medical Oncology Evans Memorial Department of Clinical ResearchBoston University Medical CenterBostonUSA
  2. 2.Departments of Medicine and PharmacologyBoston University Medical CenterBostonUSA
  3. 3.Hubert H. Humphrey Cancer Research CenterBoston University Medical CenterBostonUSA

Personalised recommendations